European Medicines Association (EMA) statement on Obeticholic acid (Ocaliva) for the treatment of primary biliary cholangitis (PBC)
The European Medicines Association (EMA) issued a statement on Obeticholic acid (Ocaliva) for the treatment of primary biliary cholangitis (PBC) on 28 06 2024.
The EMA has recommended that the marketing authorisation for Ocaliva be revoked in the European Union following results of the COBALT trial, 747-302 . In the UK EMA recommendations do not apply, as we are regulated by the Medicines and Healthcare products Regulatory Agency (MHRA). At present, there are no changes to the recommendations on use of Obeticholic acid in PBC from the MHRA or the National Institute for Health and Care Excellence (NICE) and so current prescribing practices should NOT change.
We shall update the UK liver community if there are any changes to the recommendations on the use of Obeticholic acid.
Apply for the Web Education Online Deputy Editor role
The BSG Education Committee is looking for a BSG member to join the BSG Education Online Editorial team as a Web Education Online Deputy Editor.
Call for World Gastroenterology Organisation (WGO) nominations
The World Gastroenterology Organisation (WGO) is seeking nominations for positions for the 2026-2027 term of service and invites you to nominate individuals for consideration. Serving on a committee offers a great opportunity to impact the future of WGO in a meaningful way!
GIRFT Gastroenterology Speciality Advisor Advert
The Getting It Right First Time (GIRFT) programme is looking to appoint a national gastroenterology specialty advisor to support reducing unwarranted variation, with a focus on developing pathways, sharing best practice as well as providing focused support for challenged trusts